Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Oct;26(4):455–462. doi: 10.1111/j.1365-2125.1988.tb03405.x

The effect of concurrent aspirin upon plasma concentrations of tenoxicam.

R O Day 1, P D Paull 1, S Lam 1, B R Swanson 1, K M Williams 1, D N Wade 1
PMCID: PMC1386568  PMID: 3190995

Abstract

1. The effect of chronic, high-dose aspirin therapy upon the disposition of a single dose and multiple doses of tenoxicam was examined in normal volunteers. 2. Aspirin caused a 24% drop in the t1/2 (P less than 0.005), a 49% rise in the volume of distribution (P less than 0.0003) and a 98% increase in the clearance (P less than 0.0001) of tenoxicam after a single dose of the tenoxicam. 3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment. 4. Tenoxicam percentage free measured in plasma from a normal volunteer was 0.56 +/- 0.05% over the tenoxicam concentration range 1-20 micrograms ml-1 and rose to 1.24 +/- 0.07% in the presence of aspirin 150 micrograms ml-1. 5. The effect of aspirin upon the disposition of tenoxicam was consistent with a competitive protein binding interaction.

Full text

PDF
455

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bird H. A., Allen J. G., Dixon J. S., Wright V. A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. Br J Rheumatol. 1985 Nov;24(4):351–356. doi: 10.1093/rheumatology/24.4.351. [DOI] [PubMed] [Google Scholar]
  2. Day R. O., Furst D. E., Dromgoole S. H., Kamm B., Roe R., Paulus H. E. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharmacol Ther. 1982 Jun;31(6):733–740. doi: 10.1038/clpt.1982.103. [DOI] [PubMed] [Google Scholar]
  3. Day R. O., Graham G. G., Champion G. D., Lee E. Anti-rheumatic drug interactions. Clin Rheum Dis. 1984 Aug;10(2):251–275. [PubMed] [Google Scholar]
  4. Day R. O., Lam S., Paull P., Wade D. Effect of food and various antacids on the absorption of tenoxicam. Br J Clin Pharmacol. 1987 Sep;24(3):323–328. doi: 10.1111/j.1365-2125.1987.tb03176.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Day R. O., Shen D. D., Azarnoff D. L. Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates. Clin Pharmacokinet. 1983 May-Jun;8(3):263–271. doi: 10.2165/00003088-198308030-00005. [DOI] [PubMed] [Google Scholar]
  6. Dunagan F. M., McGill P. E., Kelman A. W., Whiting B. Quantitation of dose and concentration-effect relationships for fenclofenac in rheumatoid arthritis. Br J Clin Pharmacol. 1986 Apr;21(4):409–416. doi: 10.1111/j.1365-2125.1986.tb05215.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Esquivel M., Cussenot F., Ogilvie R. I., East D. S., Shaw D. H., Jr Interaction of isoxicam with acetylsalicylic acid. Br J Clin Pharmacol. 1984 Oct;18(4):567–571. doi: 10.1111/j.1365-2125.1984.tb02505.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Francis R. J., Allen J. G., Looi D., Dixon J. S., Bird H. A., Wright V. Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. Eur J Drug Metab Pharmacokinet. 1987 Jan-Mar;12(1):59–63. doi: 10.1007/BF03189862. [DOI] [PubMed] [Google Scholar]
  9. Francis R. J., Dixon J. S., Lowe J. R., Harris P. A. The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. Eur J Drug Metab Pharmacokinet. 1985 Oct-Dec;10(4):309–314. doi: 10.1007/BF03189758. [DOI] [PubMed] [Google Scholar]
  10. Furst D. E., Blocka K., Cassell S., Harris E. R., Hirschberg J. M., Josephson N., Lachenbruch P. A., Trimble R. B., Paulus H. E. A controlled study of concurrent therapy with a nonacetylated salicylate and naproxen in rheumatoid arthritis. Arthritis Rheum. 1987 Feb;30(2):146–154. doi: 10.1002/art.1780300204. [DOI] [PubMed] [Google Scholar]
  11. Gonzalez J. P., Todd P. A. Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987 Sep;34(3):289–310. doi: 10.2165/00003495-198734030-00001. [DOI] [PubMed] [Google Scholar]
  12. Graham G. G., Day R. O., Champion G. D., Lee E., Newton K. Aspects of the clinical pharmacology of non-steroidal anti-inflammatory drugs. Clin Rheum Dis. 1984 Aug;10(2):229–249. [PubMed] [Google Scholar]
  13. Grennan D. M., Ferry D. G., Ashworth M. E., Kenny R. E., Mackinnon M. The aspirin-ibuprofen interaction in rheumatoid arthritis. Br J Clin Pharmacol. 1979 Nov;8(5):497–503. doi: 10.1111/j.1365-2125.1979.tb01033.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Heintz R. C., Guentert T. W., Enrico J. F., Dubach U. C., Brandt R., Jeunet F. S. Pharmacokinetics of tenoxicam in healthy human volunteers. Eur J Rheumatol Inflamm. 1984;7(2):33–44. [PubMed] [Google Scholar]
  15. Orme M. L. Plasma concentrations and therapeutic effect of anti-inflammatory and anti-rheumatic drugs. Pharmacol Ther. 1982;16(2):167–180. doi: 10.1016/0163-7258(82)90052-3. [DOI] [PubMed] [Google Scholar]
  16. Rumble R. H., Brooks P. M., Roberts M. S. Metabolism of salicylate during chronic aspirin therapy. Br J Clin Pharmacol. 1980 Jan;9(1):41–45. doi: 10.1111/j.1365-2125.1980.tb04794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sudlow G., Birkett D. J., Wade D. N. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976 Nov;12(6):1052–1061. [PubMed] [Google Scholar]
  18. TRINDER P. Rapid determination of salicylate in biological fluids. Biochem J. 1954 Jun;57(2):301–303. doi: 10.1042/bj0570301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Willkens R. F., Segre E. J. Combination therapy with naproxen and aspirin in rheumatoid arthritis. Arthritis Rheum. 1976 Jul-Aug;19(4):677–682. doi: 10.1002/1529-0131(197607/08)19:4<677::aid-art1780190404>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES